These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25216888)

  • 1. Apremilast, albiglutide, and empagliflozin.
    Hussar DA; Yenner S
    J Am Pharm Assoc (2003); 2014; 54(5):562-6. PubMed ID: 25216888
    [No Abstract]   [Full Text] [Related]  

  • 2. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
    Okamura T; Koiwai K
    Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-inflammatory potential of Empagliflozin.
    Pirklbauer M
    Inflammopharmacology; 2021 Apr; 29(2):573-576. PubMed ID: 33728540
    [No Abstract]   [Full Text] [Related]  

  • 4. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 5. Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death.
    Everett BM; Hiatt WR
    Circulation; 2016 Sep; 134(10):773-5. PubMed ID: 27601559
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug updates and approvals: 2014 in review.
    Sigler J
    Nurse Pract; 2014 Dec; 39(12):14-23; quiz 23-4. PubMed ID: 25350291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):13S-19. PubMed ID: 28151517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 11. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer.
    Sezer H; Yazıcı D; Deyneli O; Meriçöz Ç; Esin A; Alper E
    Endokrynol Pol; 2020; 71(3):283-284. PubMed ID: 32154575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks.
    Erskine D
    Drug Ther Bull; 2020 Mar; 58(3):34. PubMed ID: 32102786
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin in diabetes: A therapeutic light at the end of the cardiovascular tunnel?
    Grant PJ
    Diab Vasc Dis Res; 2015 Nov; 12(6):394-5. PubMed ID: 26493599
    [No Abstract]   [Full Text] [Related]  

  • 17. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Anker SD; Ponikowski P; Wanner C; Pfarr E; Hauske S; Peil B; Salsali A; Ritter I; Koitka-Weber A; Brueckmann M; Lindenfeld J; Abraham WT;
    Circulation; 2021 Oct; 144(15):1265-1267. PubMed ID: 34397263
    [No Abstract]   [Full Text] [Related]  

  • 18. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Empagliflozin improves cardiovascular prognosis].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Mar; 158(5):70. PubMed ID: 26979229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.